Valproic Acid in Childhood Progressive Brain Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01861990|
Recruitment Status : Withdrawn (Feasibility of the trial was proven to be absent.)
First Posted : May 24, 2013
Last Update Posted : May 22, 2015
|Condition or disease||Intervention/treatment||Phase|
|Pediatric Brain Tumor Glioma Anaplastic Astrocytoma Medulloblastoma Glioblastoma||Drug: Valproic Acid||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Valproic Acid for Children With Recurrent and Progressive Brain Tumors|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Experimental: Treatment arm
All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
Drug: Valproic Acid
All participants enrolled on valproic acid arm.
Other Name: Valproate, VPA, Depakote, Depakote ER, Depakene
- Completion of protocol [ Time Frame: 2 months ]Number of participants completing the protocol will be measured.
- Time to progression [ Time Frame: 2 months ]Participants will be evaluated for progression every 2 months while on the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01861990
|United States, South Carolina|
|Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Principal Investigator:||Amy L Bredlau, MD||Medical University of South Carolina|